Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies.

doi:10.1038/s41591-021-01294-w

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies.

Nature medicine - 1 Apr 2021

Chen Rita E, Zhang Xianwen, Case James Brett, Winkler Emma S, Liu Yang, VanBlargan Laura A, Liu Jianying, Errico John M, Xie Xuping, Suryadevara Naveenchandra, Gilchuk Pavlo, Zost Seth J, Tahan Stephen, Droit Lindsay, Turner Jackson S, Kim Wooseob, Schmitz Aaron J, Thapa Mahima, Wang David, Boon Adrianus C M, Presti Rachel M, O'Halloran Jane A, Kim Alfred H J, Deepak Parakkal, Pinto Dora, Fremont Daved H, Crowe James E, Corti Davide, Virgin Herbert W, Ellebedy Ali H, Shi Pei-Yong, Diamond Michael S

Abstract excerpt

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the global COVID-19 pandemic. Rapidly spreading SARS-CoV-2 variants may jeopardize newly introduced antibody and vaccine countermeasures. Here, using monoclonal antibodies (mAbs), animal immune sera, human convalescent sera and human sera from recipients of the BNT162b2 mRNA vaccine, we report the impact on antibody neutralization of a panel...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Neutralizing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Viral

Share to Chlorocebus aethiops

Share to COVID-19 Vaccines

Share to Neutralization Tests

Share to SARS-CoV-2

Share to Spike Glycoprotein, Coronavirus

Share to Vero Cells

Source

Open in PubMed Open full text

Identifiers

PMID: 33664494
DOI: 10.1038/s41591-021-01294-w
PMCID: PMC8058618

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies.PMID 33664494Read ↗

SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodiesSemantic proximity Read ↗

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.Semantic proximity Read ↗

In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strainsSemantic proximity Read ↗

Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium studySemantic proximity Read ↗

SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera.Semantic proximity Read ↗

Broadly-Neutralizing Antibodies Against Emerging SARS-CoV-2 Variants.Semantic proximity Read ↗

Cross neutralization of emerging SARS-CoV-2 variants of concern by antibodies targeting distinct epitopes on spikeSemantic proximity Read ↗

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunitySemantic proximity Read ↗

Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19.Semantic proximity Read ↗

Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization.Semantic proximity Read ↗

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines.Semantic proximity Read ↗

SARS-CoV-2 variants resist antibody neutralization and broaden host ACE2 usageSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.